The shoulder joint is one of the most comfortable for ultrasound, especially because many pathological changes occur in its soft tissues. Because of the low information content of the X-ray method, reflection of soft-tissue changes was allowed by ultrasound along with MRT to become leading in the study of the shoulder joint.
In most cases, patients with osteoarthritis have no changes in blood and urine tests, except for cases of synovitis with significant effusion, when there may be an increase in ESR, hypergammaglobulinemia, an increase in the level of the acute phase indices - CRP, fibrinogen, etc.
Improvement in recent years of specific and sensitive biochemical markers, reflecting the overall rate of bone formation and resorption, significantly improved the noninvasive assessment of bone metabolism in various metabolic bone diseases. As is known, biochemical markers are divided into markers of bone formation and bone resorption.
Various rheumatological and non-rheumatological organizations (for example, EULAR, FDA, SADOA, ORS) have published recommendations on the design of osteoarthrosis research.
The recommendations of the Osteoarthritis Research Society (ORS) are based on the division of anti-arthritis drugs proposed by the WHO and ILAR into two groups: symptomatic (fast and slow) and modifying the cartilage structure.
Pharmacoeconomics is a science whose aim is to economically assess the effectiveness of costs and results associated with the use of medicines. In Western Europe, it has been developing since the 60-70s of the XX century.
Already in the early stages of osteoarthrosis of large joints (mainly knee and hip) patients of working age are taken to dispensary records.
Systemic enzyme therapy (SET) was developed in 1954 by M. Wolff and K. Ransberger and is successfully used in Europe and the US in the treatment of various diseases accompanied by an inflammatory syndrome.
Virtually all drugs used in the treatment of patients with osteoarthritis (NSAIDs, depot-GCS, hyaluronic acid, chondroitin sulfate, etc.), have a symptomatic effect, but differ in the rate of onset of the effect
A new direction in the symptomatic treatment of osteoarthritis and other diseases of the musculoskeletal system is the use of combined inhibitors of cyclooxygenase and lipoxygenase - COX and LOG.